Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-26
2008-10-07
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S228200, C514S235800, C514S253090, C514S254090, C540S598000, C544S062000, C544S121000, C544S364000, C544S373000
Reexamination Certificate
active
07432255
ABSTRACT:
The present invention relates to compounds of formula I and their pharmaceutically acceptable salts wherein in formula I is:wherein R1to R4are as defined in the description and claims. The compounds of the present invention are useful for the treatment and/or prevention of diseases which are associated with the modulation of histamine 3 (H3) receptors.
REFERENCES:
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 4931463 (1990-06-01), Barbier et al.
patent: 4983746 (1991-01-01), Barbier et al.
patent: 5175186 (1992-12-01), Barbier et al.
patent: 5246960 (1993-09-01), Barbier et al.
patent: 5274143 (1993-12-01), Ramig et al.
patent: 5399720 (1995-03-01), Karpf et al.
patent: 5420305 (1995-05-01), Ramig et al.
patent: 6004996 (1999-12-01), Shah et al.
patent: 185 359 (1986-06-01), None
patent: 189 577 (1986-08-01), None
patent: 443 449 (1991-08-01), None
patent: 524 495 (1993-01-01), None
patent: WO 99/34786 (1999-07-01), None
patent: WO 00/09122 (2000-02-01), None
patent: WO 00/09123 (2000-02-01), None
patent: WO 00/58293 (2000-10-01), None
patent: WO 01/74773 (2001-10-01), None
patent: WO 01/74814 (2001-10-01), None
patent: WO 02/47145 (2002-06-01), None
patent: WO 2005/123716 (2005-12-01), None
patent: WO 2006/077024 (2006-07-01), None
patent: 2007/115938 (2007-10-01), None
Burks in Johnson L.R. ed., Physiology of the Gastrointestinal Tract, Raven Press, NY, pp. 211-242 (1994).
Leurs et al., Br J. Pharmacol., 102, pp. 179-185 (1991).
Raithel et al., Int. Arch. Allergy Immunol., 108, pp. 127-133 (1995).
Panula et al., Proc. Natl. Acad. Sci. USA, 81, pp. 2572-2576 (1984).
Inagaki et al., J. Comp. Neurol., 273, pp. 283-300 (1988).
Arrang et al., Nature, 302, pp. 832-837 (1983).
Arrang et al., Neuroscience, 23, pp. 149-157 (1987).
Clapham et al., Br. J. Pharmacol., 107, pp. 919-923 (1992).
Blandina et al. in The Histamine H3 Receptor (Leurs, R.L. and Timmermann, H. eds, pp. 27-40 (1998) Elsevier, Amsterdam, The Netherlands.
Masaki et al., Endocrinol., 144, pp. 2741-2748 (2003).
Hancock et al., European J. of Pharmacol., 487, pp. 183-197 (2004).
Timmermann, J. Med. Chem., 33, pp. 4-11 (1990).
Takahashi et al., J. Pharmacol. Exp. Therapeutics, 307, pp. 213-218 (2003).
Cheng., Biochem Pharmacol, 22, pp. 3099-3108 (1973).
Nettekoven Matthias Heinrich
Roche Olivier
Bernhardt Emily
Hoffmann-La Roche Inc.
Johnston George W.
Remy Brian C.
Tramaloni Dennis P.
LandOfFree
1H-indol-5-yl-piperazin-1-yl-methanone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1H-indol-5-yl-piperazin-1-yl-methanone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1H-indol-5-yl-piperazin-1-yl-methanone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3997545